Tigecycline 100 Mg Injection Suppliers & Bulk Manufacturers
Available Forms: solution for injection
Available Strengths: 50mg, 100 mg
Reference Brands: Tigene (India), Tygacil (USA/EU)
Category:
Antibiotics
Antibiotic
Tigecycline 100 mg Injection is available in solution for injection
and strengths such as 50mg, 100 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Tigecycline 100 mg Injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Tigecycline 100 mg Injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Tigecycline is a broad-spectrum antibiotic and the first drug in the glycylcycline class, developed to address infections caused by resistant bacteria. It is structurally related to the tetracycline antibiotic minocycline, but specific modifications to its molecular structure have expanded its antibacterial activity and reduced the likelihood of resistance compared with older tetracycline antibiotics. Tigecycline is effective against a wide range of bacteria, including many drug-resistant gram-positive organisms as well as certain gram-negative and anaerobic pathogens.
This antibiotic is commonly used for the treatment of complicated intra-abdominal infections and complicated skin and skin structure infections, particularly when other treatment options may not be suitable. Tigecycline is administered intravenously, typically beginning with a loading dose followed by regular maintenance dosing to maintain effective therapeutic levels in the body.
Clinical studies have demonstrated the effectiveness of tigecycline in managing serious bacterial infections. The most frequently reported side effects include nausea, vomiting, and diarrhea, which may occur during treatment and in some cases lead to discontinuation. Overall, tigecycline is an important option in modern antimicrobial therapy, especially for infections involving multidrug-resistant bacteria where alternative treatments are limited.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing